GEN three-lens brief
Evidence-based stock research on GEN. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Underperforming SPY by 16.5pp over 30 days. · Trading at 9% of its 52-week range — deep in the lower band.
- Trading at 9% of its 52-week range — deep in the lower band.
- Underperforming SPY by 16.5pp over 30 days.
- Analyst mean target $30.01 — 58% above current (11 analysts).
- Debt-to-equity of 363.4 — balance-sheet-heavy.
GEN closed at $19.04 (+1.22%) as of 2026-04-25. Market cap: $11.53B. P/E (trailing) 19.6. Positives: analyst mean target $30.01 — 58% above current (11 analysts).. Concerns: trading at 9% of its 52-week range — deep in the lower band.; underperforming SPY by 16.5pp over 30 days.. Last quarter: Revenue $1.24B, net income $192.00M, free cash flow $1.32B.
Why three lenses on GEN, not one.
A single reasoning model has blind spots it doesn’t know about. We examine GENacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/GEN" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath GEN brief"></iframe>